Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy

[1]  N. Munshi,et al.  Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial , 2017 .

[2]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[3]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[4]  A. Kassim,et al.  Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity , 2016, Bone Marrow Transplantation.

[5]  M. Jeffreys,et al.  Age disparities in survival from lymphoma and myeloma: a comparison between US and England , 2014, British journal of haematology.

[6]  S. Rajkumar,et al.  Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and management , 2012, American journal of hematology.

[7]  M. Dimopoulos,et al.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.

[8]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[9]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[10]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[11]  L. Escoda,et al.  Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[13]  H. van de Velde,et al.  Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma , 2007, Haematologica.

[14]  P. Hari,et al.  Minimal residual disease testing after stem cell transplantation for multiple myeloma , 2016, Bone Marrow Transplantation.

[15]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[16]  M. Terol,et al.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.